drugset / Trial / NCT03824964
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Phase 0
Unknown
10 enrolled
Allife Medical Science and Technology Co., Ltd.
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.
Timeline
- Start
- 2019-02-01
- Primary completion
- 2020-01-01
- Completion
- 2021-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19/BCMA CAR-T cells | Cell therapy | 50000 cells/kg | — |
| Subject | anti-CD19/BCMA CAR-T cells | Cell therapy | 600000 cells/kg | — |